From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Phase | Other agent | Disease (pt. No.) | Schedule | Recommended dose & response | Reference |
---|---|---|---|---|---|
I | ATRA(80 mg/m2) | AML (58). | Twice a day | VPA serum concentration to 50-100 ug/ml | [131] |
I | Â | Cervical cancer(12) | Once a day | 20-40 mg/kg | [137] |
I | ATRA(45 mg/m2) | AML(26) | Once a day | 5-10 mg/kg | [132] |
I | Decitabine (5 mg/m2) | NSCLC(8) | 5-aza-CdR for 10 days in combination with VA on days 5-21 of a 28-day cycle. | 15 mg/kg/d | [140] |
I | Â | Refractory advanced cancer(26) | Daily for 5 days in a 21-day cycle | 60 mg/kg/day | [138] |
I | Epirubicin | Solid tumor(44) | Daily for three days then followed by epirubicin in 21 day cycle | VPA 140 mg/kg/d Epirubincin 100 mg/m2 | [139] |
I | AZA and ATRA | AML(49) and MDS(4) | Â | VPA 75 mg/kg | [136] |
I and II | Decitabine(15 mg/m2) | AML(54) | Once a day | 50 mg/kg, 22% objective response | [134] |